Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 1:09 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 785 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Gene Expression Clear all

Conditions: Alzheimer's Disease, Dementia
Interventions: Placebo, Medication Therapy Management (MTM), Scopolamine patch; Other · Drug
Lead sponsor: Daniela Moga; Other
Eligibility: 65 Years to 101 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Breast Pumping
Interventions: Not listed
Lead sponsor: Nemours Children's Clinic; Other
Eligibility: 18 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Wilmington, Delaware

Conditions: Cancer, Hematopoietic Stem Cell Transplantation
Interventions: Emotional expression; Behavioral
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 21 Years and older
Enrollment: 122 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Osteoarthritis, Knee, Pain, Physical Activity, Mitochondrial Pathology
Interventions: Walking; Behavioral
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 50 Years to 80 Years
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy Volunteer, Prostate CA
Interventions: Piflufolastat F18; Drug
Lead sponsor: Akiva Mintz; Other
Eligibility: 18 Years to 120 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Englewood, New Jersey

Conditions: Metastatic NSCLC
Interventions: GRN-1201 + Pembrolizumab; Biological
Lead sponsor: BrightPath Biotherapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 11
States / cities: Orange, California • Aurora, Colorado • Orlando, Florida + 7 more

Conditions: Ventricular Tachycardia, Cardiovascular Diseases, Arrythmia, CVD
Interventions: Not listed
Lead sponsor: CardioDx; Industry
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Prostate Cancer Aggressiveness, Prostate Carcinoma
Interventions: Cabazitaxel, Carboplatin, Prednisone 5Mg, Olaparib; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Pancreatic Cancer
Interventions: mFOLFIRINOX Treatment Regimen, Gemcitabine/Nab-paclitaxel Treatment Regimen; Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 2
States / cities: Scottsdale, Arizona • Milwaukee, Wisconsin

Conditions: Breastfeeding
Interventions: FamilyLink Pumping, Standard Pumping; Behavioral
Lead sponsor: University of California, Davis; Other
Eligibility: Female only
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Paranoia, Psychotic Disorders
Interventions: Guided Visual Imagery Task; Behavioral
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 480 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Bloomington, Indiana

Conditions: Childhood Kidney Neoplasm, Clear Cell Renal Cell Carcinoma, Congenital Mesoblastic Nephroma, Rhabdoid Tumor of the Kidney
Interventions: Laboratory Biomarker Analysis; Other
Lead sponsor: Children's Oncology Group; Network
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2012
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Urothelial Carcinoma
Interventions: Not listed
Lead sponsor: Seagen, a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 389 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 11
States / cities: Phoenix, Arizona • Orange, California • Palo Alto, California + 8 more

Conditions: Healthy, Asthma
Interventions: JNJ-43260295, Placebo, Nasal Allergen Challenge; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Short Segment Barrett's Esophagus, Long Segment Barrett's Esophagus
Interventions: Omeprazole, Vitamin D3, upper endoscopy, Metformin; Drug · Procedure
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 3
States / cities: Beachwood, Ohio • Cleveland, Ohio

Conditions: Breast Cancer
Interventions: Intrinsic Subtyping of Primary Breast Cancer; Device
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years to 99 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2030
U.S. locations: 2
States / cities: Chapel Hill, North Carolina • Raleigh, North Carolina

Conditions: Type 2 Diabetes, Impaired Renal Function
Interventions: Linagliptin, Placebo; Drug
Lead sponsor: George Washington University; Other
Eligibility: 30 Years to 70 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Healthy
Interventions: Not listed
Lead sponsor: Arkansas Children's Hospital Research Institute; Other
Eligibility: 18 Years to 38 Years · Female only
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2019
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Duchenne Muscular Dystrophy
Interventions: delandistrogene moxeparvovec; Genetic
Lead sponsor: Sarepta Therapeutics, Inc.; Industry
Eligibility: 2 Years and older · Male only
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 12
States / cities: Little Rock, Arkansas • La Jolla, California • Los Angeles, California + 9 more

Conditions: Non Small Cell Lung Cancer, Cervical Cancer, Head and Neck Squamous Cell Cancer, Triple Negative Breast Cancer (TNBC), Urothelial Carcinoma Bladder, Gastroesophageal Junction (GEJ) Adenocarcinoma, Esophageal Squamous Cell Cancer, Gastric Cancer, Cancer, Solid Tumors (Phase 1)
Interventions: RNDO-564, Pembrolizumab; Drug
Lead sponsor: Rondo Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 11
States / cities: San Francisco, California • New Haven, Connecticut • Grand Rapids, Michigan + 8 more

Conditions: Adenomatous Polyps
Interventions: Curcuminoids; Dietary Supplement
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2012
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Bladder Cancer, Urethral Cancer
Interventions: Recombinant Interferon Alfa; Biological
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2015
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Lupus, Fibromyalgia (FM), Chronic Widespread Pain
Interventions: Emotional Awareness and Expression Therapy (EAET); Behavioral
Lead sponsor: University of Utah; Other
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Uveitis
Interventions: Not listed
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 21 Years and older
Enrollment: 280 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2005
U.S. locations: 1
States / cities: Portland, Oregon

Search by objective public record fields.

The INCREASE Study - Delaying the Onset of Alzheimer's Symptomatic Expression

Testing of New Method in Sanitizing Breast Pump Equipment in the NICU

Spouses/Partners Expressing Their Thoughts After Transplant

Biologic Mechanisms for Pain Variation After Physical Activity in Osteoarthritis

Ultralow Dose PET Imaging for PSMA Expression

GRN-1201 With Pembrolizumab in Subjects With Metastatic PD-L1+ NSCLC

Genetic Substudy of the Alternans Before Cardioverter Defibrillator (ABCD) Trial

Study of Olaparib Maintenance Following Cabazitaxel-Carbo in Men With AVPC

PurIST Classification-Guided Adaptive Neoadjuvant Chemotherapy by RNA Expression Profiling of EUS Aspiration Samples

FamilyLink and Breastfeeding

Racial Disparities in the Expression of Paranoia

Studying Biomarkers in Samples From Younger Patients With Kidney Cancer

HER2 and LA/mUC: A Multi-country Chart Review Cohort Study

Study to Examine the Cytokine Levels, Gene Expression and Safety of a Single Nasal Dose of JNJ-43260295, in Healthy Participants, and Atopic Participants With Mild to Mild-Persistent Asthma

Vitamin D Supplementation on 15-Prostaglandin Dehydrogenase Expression in Barrett's Esophagus

Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA

Linagliptin's Effect on CD34+ Stem Cells

Effect of Body Composition and Metabolism on Oocyte Gene Expression

A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD) - Non-Ambulatory Cohort

A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4

Curcumin for the Chemoprevention of Colorectal Cancer

Short-Term Low-Dose Interferon Alfa in Treating Patients With Cancer of the Urothelium

Helping Lupus Patients Manage Fibromyalgia Symptoms Through Emotional Awareness and Expression Therapy (EAET)

Uveitis Gene-Expression Profiling